Invesaro

Stocks Comparison

Cryo Cell International vs Davita: revenue, profit, margins and growth compared

Cryo Cell International brought in $31.6M of revenue in fiscal 2025, Davita $13.6B in fiscal 2025. Revenue changed by -1.3% at Cryo Cell International and +6.5% at Davita on the year before, so Davita grew faster. Cryo Cell International kept -7.7% of its revenue as net profit, Davita 5.5%. Free cash flow was $5.2M at Cryo Cell International and $1.3B at Davita.

Side by side, latest fiscal year

CCELDVA
Fiscal year endedFY2025 (November 30, 2025)FY2025 (December 31, 2025)
Revenue$31.6M$13.6B
Revenue growth-1.3%+6.5%
Net income-$2.4M$746.8M
Net margin-7.7%5.5%
Free cash flow$5.2M$1.3B
Free cash flow margin16.6%9.6%
Earnings per share (diluted)-$0.30$9.84
Cash$319K$676.4M
Debt$8.4M$10.3B
Price to earningsn/a18.1
Market value$34.2M$11.4B
Dividend yieldn/an/a
Rank by revenue in sector#412 of 646 · Health care#37 of 646 · Health care

Over the years

Revenue
CCEL FY2018: $29.2MCCEL FY2019: $31.8MCCEL FY2020: $31.1MCCEL FY2021: $28.9MCCEL FY2022: $30.3MCCEL FY2023: $31.3MCCEL FY2024: $32MCCEL FY2025: $31.6MDVA FY2018: $11.4BDVA FY2019: $11.4BDVA FY2020: $11.6BDVA FY2021: $11.6BDVA FY2022: $11.6BDVA FY2023: $12.1BDVA FY2024: $12.8BDVA FY2025: $13.6BFY18FY19FY20FY21FY22FY23FY24FY25
CCEL $31.6MDVA $13.6B
Net income
CCEL FY2018: -$854.8KCCEL FY2019: $2.3MCCEL FY2020: $3.6MCCEL FY2021: $2.1MCCEL FY2022: $2.8MCCEL FY2023: -$9.5MCCEL FY2024: $402.1KCCEL FY2025: -$2.4MDVA FY2018: $159.4MDVA FY2019: $811MDVA FY2020: $773.6MDVA FY2021: $978.5MDVA FY2022: $560.4MDVA FY2023: $691.5MDVA FY2024: $936.3MDVA FY2025: $746.8MFY18FY19FY20FY21FY22FY23FY24FY25
CCEL -$2.4MDVA $746.8M
Net margin
CCEL FY2018: -2.9%CCEL FY2019: 7.2%CCEL FY2020: 11.6%CCEL FY2021: 7.2%CCEL FY2022: 9.1%CCEL FY2023: -30.4%CCEL FY2024: 1.3%CCEL FY2025: -7.7%DVA FY2018: 1.4%DVA FY2019: 7.1%DVA FY2020: 6.7%DVA FY2021: 8.4%DVA FY2022: 4.8%DVA FY2023: 5.7%DVA FY2024: 7.3%DVA FY2025: 5.5%FY18FY19FY20FY21FY22FY23FY24FY25
CCEL -7.7%DVA 5.5%
Revenue growth
CCEL FY2019: +8.9%CCEL FY2020: -2.1%CCEL FY2021: -7.3%CCEL FY2022: +5.0%CCEL FY2023: +3.3%CCEL FY2024: +2.0%CCEL FY2025: -1.3%DVA FY2019: -0.1%DVA FY2020: +1.4%DVA FY2021: +0.6%DVA FY2022: -0.1%DVA FY2023: +4.6%DVA FY2024: +5.6%DVA FY2025: +6.5%FY19FY20FY21FY22FY23FY24FY25
CCEL -1.3%DVA +6.5%
Free cash flow
CCEL FY2018: $4.9MCCEL FY2019: $5.6MCCEL FY2020: $8.4MCCEL FY2021: $6.1MCCEL FY2022: -$3.6MCCEL FY2023: $2.1MCCEL FY2024: $3.6MCCEL FY2025: $5.2MDVA FY2018: $784.5MDVA FY2019: $1.3BDVA FY2020: $1.3BDVA FY2021: $1.3BDVA FY2022: $961.1MDVA FY2023: $1.5BDVA FY2024: $1.5BDVA FY2025: $1.3BFY18FY19FY20FY21FY22FY23FY24FY25
CCEL $5.2MDVA $1.3B

Fiscal years as each company reports them; the two may end in different months.

Questions about Cryo Cell International and Davita

Which is bigger by revenue, Cryo Cell International or Davita?

Davita is bigger by revenue: $13.6B in fiscal 2025, against $31.6M for Cryo Cell International in fiscal 2025.

Which keeps more of its revenue as profit, Cryo Cell International or Davita?

Cryo Cell International had a net margin of -7.7% in fiscal 2025; Davita had 5.5% in fiscal 2025.

Which grew revenue faster, Cryo Cell International or Davita?

In their latest fiscal years revenue changed by -1.3% at Cryo Cell International and +6.5% at Davita.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies